Found's compounded semaglutide costs $289 month-to-month or $169 with 12-month prepay; PlexusDx runs $189 month-to-month and $149 on a six-month plan. We compare all-in costs, plan flexibility, and service features across the low-cost field.

Found's advertised $99/month figure requires insurance; its cash-pay compounded semaglutide costs $289 month-to-month or $169/month prepaid annually.

Found's monthly cash plan bills 13 times per year; its 12-month prepaid plan locks in a lower effective rate but requires an upfront lump sum. We calculate the true annual cost of each option and show where PlexusDx falls in the spectrum.

Found publishes plan prices but does not state whether those prices change when your semaglutide or tirzepatide dose increases. We contrast Found's monthly and prepaid tiers with programs that guarantee flat pricing at every dose.

Annual GLP-1 plans advertise steep discounts but lock you into upfront payments of $888 to $2,364. We compare prepaid effective rates against month-to-month pricing across Found, Ro, Henry Meds, PlexusDx, and others to show when the savings justify the commitment and when they don't.

Found offers insurance-eligible plans and all-in cash rates; Noom Med splits clinical support ($129/month) from medication costs. We compare pricing structures, medication options, and service models using verified evidence captured through September 2026.

Found charges $359/month for tirzepatide on a month-to-month plan, with discounts for prepaid commitments. Insurance track members pay $199/month or prepay $1,188 annually. We break down every plan, extra fees, and how billing works.

Found charges $289 monthly for compounded semaglutide on its cash-pay track, billed every four weeks; its 12-month prepaid plan costs $2,028 upfront ($169 monthly equivalent). PlexusDx charges $189 monthly with standard calendar billing and no prepayment requirement.

PlexusDx and Found both offer compounded GLP-1s, but their pricing models diverge sharply. PlexusDx leads on month-to-month cash rates; Found wins on insurance and annual prepay. Here's the breakdown.

Found offers two pricing tracks—insurance and cash pay—with monthly and annual billing options. The effective rate depends on whether you prepay, which medication you choose, and whether you use insurance. Here's what each option actually costs over 12 months.

Several telehealth programs advertise $99 monthly semaglutide. We compare Eden, Found, Mochi Health, and others against PlexusDx, normalizing introductory rates, membership fees, and prepay commitments to show the true recurring cost over 12 months.

Found charges $289 monthly for semaglutide cash-pay with app-based coaching; PlexusDx charges $189 month-to-month with optional genetics and no membership fee. We compare pricing, medications, billing cadence, and service models for switchers evaluating both programs.

Found's 12-month cash-pay semaglutide plan requires $2,028 upfront for a $169/month rate; Hims & Hers advertises $199/month with a 6-month $1,194 commitment. PlexusDx offers $189 month-to-month with no prepayment. Here's how the economics and service models compare.

Found offers separate insurance and cash-pay tracks for GLP-1 weight management. We compare the program fees, medication costs, prepay economics, and coverage models—measured against checkout-verified evidence captured September 4, 2026.

Found bundles medication into one monthly price; Ro separates membership and medication into two line items. We compare total 12-month costs, formats, and service structures using verified pricing captured September 2026.

Found's annual plans require full upfront payment but lower the effective monthly rate by $100–$120 compared to month-to-month billing. We calculate 12-month costs for both billing structures, compare them to PlexusDx multi-month rates, and show when each makes sense.

Found advertises monthly rates as low as $99, but that figure requires insurance coverage and paying $1,188 upfront for twelve months. This breakdown explains Found's two-track pricing, medication inclusion, copay layer, and how prepayment works.

Found's cash-pay program offers semaglutide at $289 monthly or $169 per month with a $2,028 annual prepay, while PlexusDx charges $189 month-to-month. How the costs compare depends on commitment and billing cadence.

Found charges no separate membership fee—clinician access, app tools, and support are included in medication cost. PlexusDx follows the same model. The decision hinges on cash affordability versus insurance coverage and bundled features.

Found offers 12-month prepaid plans and an insurance track that can serve long-term maintenance well. Whether it beats cash-pay alternatives depends on your coverage and commitment horizon. We compare Found's maintenance fit against PlexusDx cash programs.

PlexusDx offers month-to-month compounded semaglutide at $189/mo with no membership; Found bills $289/mo every 4 weeks (13 charges/year) and offers an insurance-supported track that PlexusDx does not.

Found offers checkout-verified pricing on month-to-month and prepaid plans with insurance options; Zealthy's published figures combine medication and membership fees but were not yet checkout-verified as of July 2026.

Found and Peak Wellness take different approaches to cash-pay GLP-1 treatment—Found's 12-month prepaid plans deliver the lowest per-month rates while Peak Wellness offers stronger 6-month pricing on tirzepatide and PlexusDx leads on month-to-month flexibility.

Found bills every 4 weeks and emphasizes coaching; Henry Meds ships every 45 days and offers oral semaglutide. This comparison covers month-to-month rates, prepaid totals, format differences, and 12-month cost calculations across three providers.

Embody charges $299/month semaglutide with a 6-month guarantee; Found offers insurance billing and 12-month prepaid cash; PlexusDx runs $189/month semaglutide month-to-month. Three models, different fits.

Found and Henry Meds price their GLP-1 programs on different billing clocks. We normalize both to real annual cost and map who offers which medication.

Found and WeightWatchers represent distinct approaches to weight management—one emphasizing medical assessment and prescription support, the other focusing on behavioral lifestyle change.

Found and Calibrate both offer telehealth GLP-1 access, but differ in cost, monitoring intensity, and clinical approach. Understanding your genetic predispositions in peptide pathways may help contextualize which program aligns with your personalized care preferences.

Calibrate and Found both offer telehealth-based GLP-1 weight loss programs, but differ in medication access, provider involvement, pricing, and support structures. Understanding these differences—alongside your own health profile and genetic factors—can help you make an informed choice.

This review of Found, a telehealth GLP-1 weight-loss program built on compounded medication with providers and coaching included, compares compounding standards, clinical pathways, and how PlexusDx's precision-genetics approach differs from traditional GLP-1 access models.